Oncolys Biopharma Inc
TSE:4588
Gross Margin
Oncolys Biopharma Inc
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
Country | JP |
Market Cap | 12.9B JPY |
Gross Margin |
49%
|
Country | US |
Market Cap | 293.9B USD |
Gross Margin |
66%
|
Country | US |
Market Cap | 167.6B USD |
Gross Margin |
66%
|
Country | US |
Market Cap | 115B USD |
Gross Margin |
87%
|
Country | US |
Market Cap | 108.2B USD |
Gross Margin |
86%
|
Country | AU |
Market Cap | 135.3B AUD |
Gross Margin |
52%
|
Country | US |
Market Cap | 84.4B USD |
Gross Margin |
76%
|
Country | US |
Market Cap | 50.9B USD |
Gross Margin |
22%
|
Country | US |
Market Cap | 43.1B USD |
Gross Margin |
75%
|
Country | US |
Market Cap | 33.6B USD |
Gross Margin |
75%
|
Country | KR |
Market Cap | 39.7T KRW |
Gross Margin |
48%
|
Profitability Report
View the profitability report to see the full profitability analysis for Oncolys Biopharma Inc.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Oncolys Biopharma Inc's most recent financial statements, the company has Gross Margin of 48.6%.